P2.03b-063 Molecular Profiling in Advanced Non-Small-Cell Lung Cancer: Preliminary Data of an Italian Observational Prospective Study
Élisa Gobbini(Institut Curie), Silvia Novello(University of Turin), Massimo Di Maïo(University of Siena), Saverio Cinieri(Ospedale A. Perrino), Olga Martelli(Agostino Gemelli University Polyclinic), Vieri Scotti(University of Florence), Paola Bordi, Salvatore Pisconti(Ospedale SS. Annunziata), Domenico Galetta(Istituto Tumori Bari), Emilio Bria(Università Cattolica del Sacro Cuore), Antônio Rossi(Università Campus Bio-Medico), Paolo Graziano(Pathological Society), Vanesa Gregorc(IRCCS Ospedale San Raffaele), Evaristo Maiello(Casa Sollievo della Sofferenza), Giulio Rossi(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Diego Cortinovis(Azienda Ospedaliera San Gerardo), Angelo Delmonte(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Giulia Pasello(University of Padua), L Buffoni(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Concetta Sergi(Ospedale Garibaldi), Tindara Franchina(University of Messina), Anna Ceribelli(St. Eugenio Hospital), Alice Lunghi(Azienda Ospedaliero-Universitaria Careggi), Maria Rita Migliorino(Carlo Forlanini Hospital), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 0
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Non-small-cell lung cancer
|Nature Reviews Disease Primers|2015|1.1k